MONDAY, July 7, 2025 (HealthDay News) — Adults as young as 50 may now qualify for an RSV vaccine if they have certain health ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

Just in 2024 alone, respiratory syncytial virus (RSV) claimed 2,360 lives of children in hospitals notified in Bengaluru, Kolkata and Mumbai, said Dr Vasant M Khalatkar, National President of the ...

Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

As Thailand transitions from the rainy to early winter seasons, respiratory infections surge dramatically, making awareness and proper prevention crucial. Recognising this urgent public health concern ...

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

RSV is ubiquitous, one of the most common causes of childhood illness. Most kids will catch this highly contagious respiratory virus at some point before they turn 2, according to the CDC.

Key takeaways: The FDA approved the monoclonal antibody clesrovimab-cfor for preventing RSV disease in babies. Unlike nirsevimab, which has weight-based dosing, clesrovimab has a fixed dose.

Results showed the incidence rate of RSV-associated MALRI requiring at least 1 indicator of LRI or severity through 150 days was 3.6% (95% CI, 2.0-6.0) in clesrovimab-treated patients compared ...